
Laure Marignol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3679112/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Achieving hypoxia-inducible gene expression in tumours. Cancer Biology and Therapy, 2005, 4, 365-370.	3.4	176
2	Hypoxia in prostate cancer: A powerful shield against tumour destruction?. Cancer Treatment Reviews, 2008, 34, 313-327.	7.7	112
3	MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. Journal of Molecular Medicine, 2012, 90, 1449-1458.	3.9	93
4	NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer. Nature Reviews Urology, 2014, 11, 499-507.	3.8	85
5	Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. Anticancer Research, 2016, 36, 5-12.	1.1	82
6	Hypoxia, notch signalling, and prostate cancer. Nature Reviews Urology, 2013, 10, 405-413.	3.8	78
7	DNA mismatch repair and the DNA damage response to ionizing radiation: Making sense of apparently conflicting data. Cancer Treatment Reviews, 2010, 36, 518-527.	7.7	70
8	Alterations in DNA Repair Efficiency are Involved in the Radioresistance of Esophageal Adenocarcinoma. Radiation Research, 2010, 174, 703-711.	1.5	65
9	The HIF-1α C1772T polymorphism may be associated with susceptibility to clinically localized prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biology and Therapy, 2009, 8, 118-124.	3.4	50
10	Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis. , 2017, 37, 5343-5353.		50
11	Exposure to low dose ionising radiation: Molecular and clinical consequences. Cancer Letters, 2013, 338, 209-218.	7.2	48
12	Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. International Journal of Cancer, 2013, 132, 1771-1780.	5.1	40
13	Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells. Scientific Reports, 2016, 6, 34796.	3.3	40
14	MicroRNAs as putative mediators of treatment response in prostate cancer. Nature Reviews Urology, 2012, 9, 397-407.	3.8	36
15	Exposure to low dose ionising radiation: Molecular and clinical consequences. Cancer Letters, 2014, 349, 98-106.	7.2	36
16	Metformin and improved treatment outcomes in radiation therapy – A review. Cancer Treatment Reviews, 2017, 55, 150-162.	7.7	35
17	Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1106-1116.	1.6	34
18	Recognition of O6MeG Lesions by MGMT and Mismatch Repair Proficiency may be a Prerequisite for Low-Dose Radiation Hypersensitivity. Radiation Research, 2009, 172, 405-413.	1.5	31

#	Article	IF	CITATIONS
19	Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma. Molecular Medicine, 2016, 22, 388-397.	4.4	29
20	Nomograms are key decision-making tools in prostate cancer radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 283-292.	1.6	29
21	MGMT testing allows for personalised therapy in the temozolomide era. Tumor Biology, 2016, 37, 87-96.	1.8	27
22	Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiation Oncology, 2012, 7, 75.	2.7	25
23	The Notch-1 receptor in prostate tumorigenesis. Cancer Treatment Reviews, 2017, 56, 36-46.	7.7	25
24	Determining if low dose hyper-radiosensitivity (HRS) can be exploited to provide a therapeutic advantage: A cell line study in four glioblastoma multiforme (GBM) cell lines. International Journal of Radiation Biology, 2013, 89, 1009-1016.	1.8	24
25	Therapeutic potential of melatonin for breast cancer radiation therapy patients. International Journal of Radiation Biology, 2018, 94, 472-477.	1.8	23
26	Isogenic radiation resistant cell lines: Development and validation strategies. International Journal of Radiation Biology, 2014, 90, 115-126.	1.8	22
27	Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs. Clinical and Translational Radiation Oncology, 2017, 2, 63-68.	1.7	20
28	Clinical Potential of Statins in Prostate Cancer Radiation Therapy. , 2017, 37, 5363-5372.		19
29	DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. Cancer Letters, 2010, 291, 142-149.	7.2	18
30	Radiation to control transgene expression in tumors. Cancer Biology and Therapy, 2007, 6, 1005-1012.	3.4	16
31	Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 912-919.	1.6	16
32	Standardization of assay methods reduces variability of total PSA measurements: an Irish study. BJU International, 2012, 110, 644-650.	2.5	15
33	DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells. Cancer Letters, 2013, 335, 19-25.	7.2	14
34	Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer. PLoS ONE, 2013, 8, e63723.	2.5	14
35	Hypoxia response elementâ€driven cytosine deaminase/5â€fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells <i>in vitro</i> . Journal of Gene Medicine, 2009, 11, 169-179.	2.8	13
36	Gene expression analysis in prostate cancer: The importance of the endogenous control. Prostate, 2013, 73, 382-390.	2.3	13

#	Article	IF	CITATIONS
37	YB-1: The key to personalised prostate cancer management?. Cancer Letters, 2020, 490, 66-75.	7.2	13
38	Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells. Heliyon, 2016, 2, e00104.	3.2	10
39	The Notch-3 receptor: A molecular switch to tumorigenesis?. Cancer Treatment Reviews, 2017, 60, 69-76.	7.7	10
40	68Ga-PSMA-PET/CT Ηas a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease. Anticancer Research, 2017, 37, 2753-2760.	1.1	10
41	Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies. Prostate, 2011, 71, 550-557.	2.3	9
42	Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer. Applied Radiation and Isotopes, 2015, 106, 237-241.	1.5	9
43	Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics. Cancer Letters, 2021, 498, 210-216.	7.2	9
44	Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients. Cancer Treatment Reviews, 2011, 37, 643-654.	7.7	8
45	Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. Scientific Reports, 2019, 9, 17325.	3.3	8
46	Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro. Cancer Biology and Therapy, 2011, 11, 421-428.	3.4	7
47	Pro-con of proton: Dosimetric advantages of intensity-modulation over passive scatter for thoracic malignancies. Technical Innovations and Patient Support in Radiation Oncology, 2020, 15, 37-46.	1.9	7
48	The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?. Journal of Gene Medicine, 2008, 10, 1032-1038.	2.8	6
49	Targeting notch in prostate cancer—combination is the key. Nature Reviews Urology, 2014, 11, 419-419.	3.8	6
50	Active surveillance for low-risk prostate cancer: diversity of practice across Europe. Irish Journal of Medical Science, 2015, 184, 305-311.	1.5	6
51	Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?. Tumor Biology, 2014, 35, 5095-5100.	1.8	5
52	Notch signalling: the true driver of small cell lung cancer?. Translational Cancer Research, 2017, 6, S1191-S1196.	1.0	5
53	An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?. Radiotherapy and Oncology, 2018, 128, 520-533.	0.6	4
54	Geometric and Dosimetric Evaluation of a Commercially Available Auto-segmentation Tool for Gross Tumour Volume Delineation in Locally Advanced Non-small Cell Lung Cancer: a Feasibility Study. Clinical Oncology, 2021, 33, 155-162.	1.4	4

#	Article	IF	CITATIONS
55	Influence of inter-observer delineation variability on radiomic features of the parotid gland. Physica Medica, 2021, 82, 240-248.	0.7	4
56	Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?. Anticancer Research, 2018, 38, 1897-1902.	1.1	4
57	Identification of suitable endogenous controls for gene and miRNA expression studies in irradiated prostate cancer cells. Tumor Biology, 2015, 36, 6019-6028.	1.8	3
58	Image-Guided Radiotherapy in Paediatrics: A Survey of International Patterns of Practice. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 265-269.	0.3	3
59	Active surveillance for low-risk prostate cancer: Practice across Europe Journal of Clinical Oncology, 2012, 30, 217-217.	1.6	3
60	The radiotherapy cancer patient: female inclusive, but male dominated. International Journal of Radiation Biology, 2020, 96, 851-856.	1.8	2
61	Erratum to "Exposure to low dose ionizing radiation: Molecular and clinical consequences―[Cancer Lett. 338 (2) (2013) 209–218]. Cancer Letters, 2014, 349, 97.	7.2	1
62	EP-2042: Meta-analysis: can amifostine reduce chemoradiotherapy and radiotherapy toxicity in advanced NSCLC?. Radiotherapy and Oncology, 2016, 119, S964.	0.6	1
63	Predicting Treatment Outcomes: The Case for Hypoxia Gene Signatures. EBioMedicine, 2018, 32, 3-4.	6.1	1
64	Dosimetric impact of uncorrected systematic yaw rotation in VMAT for peripheral lung SABR. Reports of Practical Oncology and Radiotherapy, 2019, 24, 520-527.	0.6	1
65	989 INVESTIGATING PROMOTER METHYLATION OF WNT SIGNALLING ANTAGONISTS IN PROSTATE CANCER. European Urology Supplements, 2010, 9, 310.	0.1	0
66	2041 DEMONSTRATION OF THE VARIABILITY OF THE DIFFERENT TOTAL PSA ASSAYS CURRENTLY IN USE THROUGHOUT IRISH HOSPITALS. Journal of Urology, 2011, 185, .	0.4	0
67	933 AN IN VITRO INVESTIGATION OF THE CYTOTOXIC AND RADIO-SENSITISING PROPERTIES OF A NOVEL MICRO- TUBULE TARGETING AGENT, PBOX-15, IN HYPOXIC PROSTATE CANCER CELL LINES. European Urology Supplements, 2011, 10, 292.	0.1	0
68	Comment on "Androgenâ€hypersensitive preclinical model of prostate cancer―by Kawata et al Prostate, 2011, 71, 559-560.	2.3	0
69	EP-1111 USE OF DWI AND ADC VALUES IN DETECTION AND STAGING OF PROSTATE CANCER OF THE CENTRAL GLAND AND THE PERIPHERAL ZONE. Radiotherapy and Oncology, 2012, 103, S429.	0.6	0
70	147 DCEMRI IN ASSESSMENT OF TUMOR NEOVASCULARIZATION AFTER ANDROGEN-DEPRIVATION IN EXPERIMENTAL PROSTATE CANCER: CORRELATION TO QUANTITATIVE IMMUNOHISTOCHEMISTRY. Radiotherapy and Oncology, 2012, 102, S68.	0.6	0
71	Effect of ROI Selection on Pharmacokinetic parameter outputs from DCE-MRI in the prostate. Physica Medica, 2013, 29, 568-569.	0.7	0
72	Radiotherapy scheduling using prime numbers. Journal of Radiotherapy in Practice, 2014, 13, 317-321.	0.5	0

#	Article	IF	CITATIONS
73	OC-0587: An assessment of compassion fatigue levels among radiation therapists working in Ireland, using the proQOL-v5. Radiotherapy and Oncology, 2014, 111, S231.	0.6	0
74	EP-1237: Identification of MiRNAs associated with radioresistance in a prostate cancer model. Radiotherapy and Oncology, 2015, 115, S670.	0.6	0
75	PO-1061: Radiosensitisation properties of PI3K/AKT inhibitor GDC-0941 in prostate cancer cells. Radiotherapy and Oncology, 2015, 115, S572.	0.6	0
76	PO-0982: Therapeutic potential of the YB-1/Notch-3 interaction in prostate cancer. Radiotherapy and Oncology, 2016, 119, S477.	0.6	0
77	SP-0007: Gene editing: How this technique can be used to study radiation responses?. Radiotherapy and Oncology, 2017, 123, S1.	0.6	0
78	PV-0371: Novel molecular radiobiology for personalised prostate cancer radiotherapy. Radiotherapy and Oncology, 2017, 123, S200.	0.6	0
79	OC-0381: Lessons from isogenic models of radioresistant prostate cancer cells. Radiotherapy and Oncology, 2018, 127, S194-S195.	0.6	0
80	Planning target volume (PTV) margin practice patterns in adults and paediatrics among the Paediatric Radiation Oncology Society (PROS) members: an international survey. Journal of Radiotherapy in Practice, 2018, 17, 368-372.	0.5	0
81	SP-036: Radiobiology of particles therapy: principles and latest advances. Radiotherapy and Oncology, 2019, 141, S15.	0.6	0
82	PO-1509 Tumours have a sex-relevance to the multifunctional oncoprotein Y-box binding protein-1 (YB-1). Radiotherapy and Oncology, 2021, 161, S1236-S1237.	0.6	0
83	PO-1800 Exploring hypoxia in prostate cancer with T2-weighted MRI radiomics and pimonidazole scoring Radiotherapy and Oncology, 2021, 161, S1526-S1527.	0.6	0
84	Sex in Bladder cancer research: an overview. SN Comprehensive Clinical Medicine, 2021, 3, 548-553.	0.6	0
85	Abstract 4904: Epigenetic discovery screen identifies SFRP2 as a novel biomarker of high grade prostate cancer. , 2010, , .		0
86	Abstract 3991: miR-31 modulates tumor sensitivity to radiation in esophageal cancer by regulation of DNA repair genes. , 2011, , .		0
87	Abstract 3444: Identification of a miRNAs signature of radioresistance in a prostate cancer model. , 2015, , .		0
88	Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer. Advances in Modern Oncology Research, 2015, 1, .	0.1	0
89	Improving non-invasive detection of prostate cancer using diffusion-weighted MRI. Advances in Modern Oncology Research, 2016, 2, 309.	0.1	0
90	Kidney Cancer Research: Sex-Inclusive but Sex-Unspecific. Clinical Oncology and Research, 2020, , 1-5.	0.0	0

#	Article	IF	CITATIONS
91	PO-1845: Time trend analysis of target volume autocontouring in locally advanced NSCLC over the course of RT. Radiotherapy and Oncology, 2020, 152, S1027-S1028.	0.6	Ο
92	PO-1564: Influence of inter-observer delineation variability on radiomics features of the parotid gland. Radiotherapy and Oncology, 2020, 152, S847.	0.6	0
93	TMOD-12. ESTABLISHING A CLINICALLY RELEVANT MODEL OF MESENCHYMAL GLIOBLASTOMA (GBM) TO STUDY RESPONSE TO STANDARD OF CARE TREATMENT AND IMMUNE CHECKPOINT INHIBITION (ICI) Neuro-Oncology, 2020, 22, ii230-ii230.	1.2	Ο
94	PO-1054 Cancer community perceptions and knowledge of Radiation Therapy as a cancer treatment. Radiotherapy and Oncology, 2022, 170, S889-S890.	0.6	0